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LITERATURE REVIEW AND RATIONALE
Abstract
Bariatric surgery is a popular and effective
treatment for obesity. However, an unfavorable
consequence for patients who have had bariatric
surgery is copper (Cu) deficiency. Current
screening methods used for Cu deficiency are
neither sensitive nor specific enough to diagnose
Cu deficiency or detect changes in Cu status.
The purpose of this research is to determine if
concentrations of copper chaperone for superoxide
dismutase (CCS) in erythrocytes are associated
with serum Cu concentrations in bariatric surgery
patients, by assessing whether changes in CCS
concentrations can be observed in response to
altering Cu status when patients are supplemented
with Cu (8 mg/day) or iron (Fe) (195 mg/day)
for 8 weeks. Blood samples were obtained from
subjects who had undergone bariatric surgery
and serum Cu concentrations were measured.
Concentrations of CCS in erythrocytes were
measured using Western blotting. CCS and serum
Cu were not significantly correlated (p > 0.05),
though there were significant increases in CCS
for patients supplemented with Fe (p < 0.05).
This indicates that CCS increases as a result
of Fe supplementation. Because serum Cu and
erythrocyte CCS were not significantly correlated,
it is unclear if CCS is representative of Cu status.
Future research should focus on improving the
reliability of the methods and increasing the
sample size.

Keywords
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minerals, iron, Western blot

Bariatric surgery is considered to be one of the most
effective treatments for obesity and is recommended
for individuals who are moderately or severely obese,
suffer from an obesity-related health condition,
and have not responded to other methods of weight
loss (Jensen et al., 2014; Sjöström et al., 2004). On
average, a patient’s BMI drops between 8–10 units
(kg/m2), with maximum weight loss 12 months
post-surgery (Schauer et al., 2014). Bariatric surgery
is also very popular; in 2013, 154,276 people with
severe obesity in the U.S. underwent the procedure
(Angrisani et al., 2015).
There are multiple types of bariatric surgery
procedures. Of those, Roux-en-Y gastric bypass
(RYGB), seen in Figure 1A, used to be the most
commonly performed bariatric surgery procedure,
but is currently declining in popularity (Angrisani et
al., 2015). In the RYGB surgery, the duodenum of the
small intestine and most of the stomach is bypassed,
leaving a 30 mL stomach pouch (MacLean, Rhode,
& Nohr, 2000). This procedure induces weight loss
through food restriction and nutrient malabsorption
(Gletsu-Miller & Wright, 2013). Another type of
bariatric surgery procedure is the sleeve gastrectomy
(SG) surgery, seen in Figure 1B, which is currently
the most popular type of bariatric surgery procedure.
In this procedure, the surgeon removes a portion
of the stomach but leaves the intestines intact. This
induces weight loss through food restriction (GletsuMiller & Wright, 2013).
There are many documented benefits of receiving
bariatric surgery. These benefits include resolution
or improvement of diseases, such as type 2 diabetes,
cardiometabolic disease, hypertension, depression,
and reduction in mortality rates (Adams et al., 2012;
Christou et al., 2004; Dixon et al., 2008; Schowalter
et al., 2007; Sjöström et al., 2007; Sjöström et
al., 2012). However, there are also some negative
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Obesity is a rising epidemic in the United States,
affecting 35% of adults (body mass index, BMI ≥
30 kg/m2), with 4.5% of men and 8% of women being
severely obese (BMI ≥ 40 kg/m2) (Flegal, Carroll,
Kit, & Ogden, 2012). It is forecasted that incidence of
moderate (BMI ≥ 35 kg/m2) and severe obesity will
continue to increase in the United States (Finkelstein
et al., 2012). Obesity is a major risk factor for several
chronic diseases, including diabetes, cardiovascular
disease, and cancer (WHO, 2016). For those patients
who wish to lose weight, there are several methods
that can be used to induce weight loss, including diet,
exercise, medication, and surgery.

Roux-en-Y Gastric

A Bypass (RYGB)

B Sleeve

Gastrectomy (SG)

Figure 1: Depiction of two common
Figure 1. Depiction of two common bariatric surgery types.
bariatric
surgery types
consequences associated with undergoing bariatric
surgery. Bariatric surgery alters dietary intake and
nutrient absorption, which may result in nutritional
deficiencies following surgery (Gletsu-Miller & Wright,
2013). Some of the nutritional complications are wellknown and screened for by health care providers,
including malnutrition of protein, vitamin B12, vitamin
D, calcium, and iron (Fe). Others that are not typically
screened for by physicians include B vitamins, fatsoluble vitamins, and minerals such as copper (Cu) and
zinc (Clements et al., 2006; Gasteyger, Suter, Gaillard,
& Giusti, 2008). Without screening, patients who have
undergone bariatric surgery are at risk for postsurgical
nutrient deficiencies that are not being monitored or
treated appropriately.
As one of the essential minerals, Cu plays many
important roles in the body by acting as a cofactor
for the enzyme function of ceruloplasmin (Cp) and
superoxide dismutase 1 (SOD1) (Homberg & Laurell,
1947). It also assists in hemoglobin formation,
cell signaling, and cellular respiration (Fox, 2003;
Haremaki Fraser, Kuo, Baron, & Weinstein, 2007).
Dietary Cu requirements are met by most healthy
adults, because it is found in commonly consumed
foods such as mushrooms, leafy green vegetables, and
even cocoa (Trumbo, Yates, Schlicker, & Poos, 2001).
However, cases of Cu deficiency have been found as
a result of bariatric surgery. Cu is absorbed mostly in
the duodenum of the small intestine, which is bypassed
in patients who have had the RYGB procedure
(Mason, 1979). A previous study reported from our
group determined that incidence of copper deficiency
following RYGB surgery was 18.8% (Gletsu-Miller et
al., 2012).
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can be altered
is through
interactions with Fe. A notable site of interaction
between Fe and Cu is the divalent metal-ion
transporter 1 (DMT1), a transporter on the
basolateral membrane of the enterocyte, where they
compete for absorption (Gulec & Collins, 2014). In
addition, both minerals need to be in their reduced
forms to be absorbed into the enterocyte, thus they
compete for reduction by cytochrome B reductase 1
(CYBRD1). Previous studies have shown that high
dietary Fe results in decreased Cu status in rats
(Jung-Heun Ha, Zhao, Wang, Flores, & Collins,
2016). Copper-transporting ATPase 1 (ATP7A) is the
primary transporter of Cu and is upregulated during
Fe deficiency, and is believed to also influence Fe
transport (Collins, Franck, Kowdley, & Ghishan,
2005). Duodenal epithelial interactions are shown
in Figure 2 (Guelc & Collins, 2014). One additional
interaction that should be noted is Cu’s function in
Fe homeostasis. Cp, a Cu binding molecule, mediates
Fe release from sites of Fe storage and into the blood
for Fe to perform essential functions (Hellman &
Gitlin, 2002).
Currently, there are several methods of assessing
Cu status. These methods include measuring
concentrations of erythrocyte SOD1, plasma Cp
activity, serum Cu, or liver Cu (Danzeisen et al.,
2007). SOD1 has not been found to be a reliable or

sensitive indicator for Cu status because erythrocyte
concentrations of SOD1 are affected by a variety of
health and stress conditions (Danzeisen et al., 2007).
Cp decreases during severe Cu deficiency but is
also an acute-phase response protein that increases
during inflammation and infection (Danzeisen
et al., 2007). This may result in falsely elevated
concentrations of Cp that could misrepresent Cu
status. Serum Cu is tightly regulated but can also
be elevated during inflammation; thus, it does not
accurately correspond to Cu status (Danzeisen et
al., 2007). Liver Cu is the only reliable Cu status
indicator; however, it is difficult to measure in
humans without an invasive procedure (Araya et
al., 2003). Thus, there is a critical need for a more
sensitive and specific biomarker to assess Cu
deficiency and changes in humans.

OBJECTIVE
The purpose of my research is to determine whether
concentrations of CCS in erythrocytes are associated
with serum concentrations of Cu in patients who
have had bariatric surgery. We will additionally
determine whether we can observe changes in
CCS concentrations in erythrocytes in response to
changes in Cu status by supplementing patients with
high doses of Cu and Fe. We expect CCS to increase
for patients supplemented with Fe and decrease
for patients supplemented with Cu. From this data,
we can evaluate whether CCS would be a viable
biomarker to test Cu status.

Human Subjects
The Purdue Institutional Review Board approved this
study (#1410015305). Postcards were used to recruit
patients who might be eligible for the study. We also
used a recruitment service called ResNet, which is
a database of patients who are receiving services
through the Indiana University Health System. To
qualify for the study, subjects must have been female,
have had RYGB or SG bariatric surgery at least 6
months prior to enrollment, and have been at least
18 years of age. All subjects gave informed consent
to participate in the study. Subjects were excluded
if they were pregnant, had received intravenous
(IV) Fe in the last month, or had surgical revisions
to bariatric surgery. Men were excluded from the
study because it is less common for men to undergo
bariatric surgery (Buchwald & Oien, 2013).

Screening
To enroll in the study, patients had to qualify at a
screening visit. Patients filled out three-day food
logs before coming in for their screening visits.
At the visit, a blood draw was performed in the
morning after the patient had undergone an 8-hour
overnight fast. Status of Fe and Cu were measured
by Mid America Clinical Laboratories (MACL,
Indianapolis, IN), a commercial reference laboratory.
Information was collected regarding demographics
and relevant medical history during an interview.
Height and weight were also measured at the patient
screening visit.
To enroll in the Fe supplementation intervention,
patients had to have Fe deficiency based on two or
more of the following criteria: ferritin < 20mcg/L,
total iron binding capacity (TIBC) > 370mcg/dL,
soluble transferrin receptor (sTfR) > 2012mcg/L, and
sTfR: ferritin ratio > 500 (Grant et al., 2012). In order
to enroll in the Cu supplementation intervention,
patients must have had Cu deficiency at two separate
screening visits, diagnosed by having a serum Cu
concentration < 70mg/dL and Cp activity in plasma
< 62.5 units/L (Gletsu-Miller et al., 2012).

Intervention
We enrolled one patient into the Cu supplementation
intervention and five patients into the Fe
supplementation intervention. We provided patients
who were enrolled in the Fe supplementation
intervention with Nature Made ferrous sulfate Fe
supplementation at a dose of 65 mg taken three times
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Studies have shown that copper chaperone for
superoxide dismutase (CCS) could be a promising
biomarker for assessing Cu status. CCS plays an
important role in delivering Cu to the antioxidant
enzyme SOD1 (Culotta et al., 1997). It was found
in rats that CCS expression is more sensitive to
mild reductions in Cu status compared to serum
Cu, SOD1, and Cp activity (Iskandar et al., 2005).
CCS is elevated in the erythrocytes of Cu-deficient
rats and mice compared to rats and mice that are
normal in Cu status, reflecting a negative correlation
between CCS and serum Cu (West & Prohaska,
2004). Since previous animal models show that
CCS is a promising biomarker for Cu status, we
would like to look at this in human subjects. In this
study, we tested CCS as a biomarker of Cu status
in bariatric surgery patients. We hypothesized that
CCS would respond to changes in Cu status in
Cu-deficient patients supplemented with copper,
where CCS was hypothesized to decrease, and when
altering Cu status in response to high doses of Fe
supplementation, where CCS was hypothesized
to increase.

METHODS

a day as recommended by the bariatric surgery
guidelines (Mechanick et al., 2013). They received
supplementation for 8 weeks with visits at weeks
one, two, four, and eight. We provided the patient
who enrolled in Cu intervention Cu gluconate
supplementation from GNC at a dose of 8 mg/day
for 8 weeks as previously determined by Griffith and
colleagues (2009).
At each study visit, enrolled patients went to the
Purdue Clinical Research Center after having
undergone an 8-hour overnight fast to have their
blood drawn. Supplements were provided at each
visit. Controls for this study were bariatric surgery
patients who had undergone screening for Fe and Cu
deficiency but were not deficient.

Fractionation of Erythrocytes
A blood draw was obtained at all visits for both
screened and enrolled patients. The blood was
fractionated to separate erythrocytes, monocytes,
and plasma as previously described (Araya et al,
2012). Measurements of serum Cu were measured as
described (Lassi & Prohaska, 2012).

Western Blotting
Western blotting assays were performed using
patients’ blood erythrocytes to test for presence of
CCS as described by Lassi and Prohaska (2012). We
did not regulate protein loading due to difficulty
quantifying erythrocyte proteins. Primary antibody,
mouse anti-rabbit polyclonal antibody against CCS,
was obtained from West and Prohaska (2004), and
diluted 1:500. Secondary antibody was obtained from
Li-Cor diluted 1:10,000. Positive controls were run
on every Western performed. We assessed CCS in
all patients who were screened regardless of whether
they were Cu-deficient or not. By assessing all
patients, we were able to determine normal reference
levels of CCS.

positive control samples run for both intraday
variation and interday variation.

RESULTS
Patient Characteristics
Table 1 shows the patient demographics and
characteristics of all screened subjects. We screened
32 subjects; all screened subjects were female. The
median age of the study population was 46 years old.
Most subjects self-identified as Caucasian (94%).
Their BMIs ranged from 22.3 to 55.9 kg/m2. Most
subjects underwent the RYGB surgery (94%), but one
subject had undergone the SG.
All Screened Patients
(N = 32)

Demographics
Age (years)
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46 (39–49)

Sex of subject,
female N (%)

100 %

Race/ethnicity (%)
CA, AA, HI

94, 3, 3

Type of surgery,
RYGB N (%)

31 (94)

Years since surgery

6.82 (3.5–10.16)

Anthropometrics
BMI (kg/m2)

STATISTICS AND DATA ANALYSIS
All data is presented as median values and
interquartile (IQ) ranges, unless otherwise specified
on the figure. Serum Cu and erythrocyte CCS
correlations were performed using Spearman
correlations for non-parametric data. Two outliers
were removed from the data before running the
statistical measures. A dependent sample T-test
was performed to compare changes in the Fe
supplemented patients’ concentrations of CCS at
visit 1 to those of visit 4. Coefficients of variation
(CV) for Western blots were calculated based on

Median
(Interquartile Range)

30.5 (26.8–36.8)
Nutritional Status

Serum Cu (μg/dL)

Ferritin (μg/L)

109 (96–124.5)

13.75 (6.4–43.78)

CA: Caucasian; AA: African American; HI: Hispanic; BMI:
body mass index.
Table 1. Screened patient characteristics.

Associations Between Erythrocyte CCS
and Serum Cu Concentration
For the CCS assay, the intraday CV was found
to be 16.1% and the interday CV was found to be
18.25%. All screened patients were used to assess
the association between erythrocye CCS and serum
Cu. Figure 3 shows the association between the
two measures. It was found that CCS and serum Cu
were not significantly correlated (p = 0.61).
180

CCS and Serum Cu in Screened Patients

Figure 3: CCS and
Serum Cu were found
not to be significantly
Five
patients were found to have Fe deficiency.
correlated. R=
-0.092,
p=0.61
Their serum Cu at screening averaged to be 145.8

Serum Cu (µg/dL)

160
140
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Figure 5. Patient supplemented with Cu gluconate
showed no change in the concentration of CCS in
erythrocytes.

0.5
1.5
2.5
3.5
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4.5

Figure 3. CCS and serum Cu were found not to be
signiﬁcantly correlated. R = -0.092, p = 0.61.

Impact of Cu and Fe Supplementation
on Erythrocyte CCS Concentrations

Figure 4. After 8 weeks of 8mg/day Cu gluconate
supplementation, the patient began with 64 μg/dL of
serum Cu and ended above a normal level at 83.4 μg/dL.
At the end of the intervention, serum Cu concentration
was above the normal reference level.

DISCUSSION
This study analyzed Cu status in normal
and deficient patients following Cu and Fe
supplementation. We evaluated whether a biomarker,
called CCS, was associated with serum Cu
concentrations, and how CCS responds to change
in Cu status following Fe and Cu supplementation.
Our study found no correlation between CCS
concentrations in erythrocytes and serum Cu.
However, a significant increase was seen in CCS
from visit 1 to visit 4 in patients who underwent Fe
supplementation. CCS concentrations in the patient
who received Cu supplementation did not change at
any point during the study.
This study did not find a significant correlation
between CCS concentrations in erythrocytes and
serum Cu, suggesting that CCS may not be a viable
biomarker for Cu status in human subjects. This
result was unexpected and contradicts previous
research performed on rats where CCS was shown
to be an effective biomarker in representing Cu
status (West & Prohaska, 2004). Additionally, it
contradicts studies done on humans that showed CCS
as a biomarker in assessing Cu toxicity (Araya et al.,
2012). As far as we know, this was the first study to
test CCS concentrations, as it relates to Cu deficiency
in human subjects. CCS may respond differently in
humans than we had expected from previous studies
conducted on rats. Because we had a high CV both
between and within assays for our Western blots,
it is possible that the assay itself was not reliably
69

Measurement of Copper Deﬁciency in Humans

The patient supplemented with Cu had a BMI of
22 kg/m 2. The patient had a serum Cu concentration
of 79.1 μg/dL on visit 1 and 83.4 μg/dL on visit 4.
Figure 4 shows the serum Cu concentrations of the
patient supplemented with Cu gluconate (8 mg/
day) for 8 weeks, where Cu status was normalized
from baseline to visit 4. Figure 5 shows the CCS
concentrations in erythrocytes before and after
Cu supplementation. There was no change in CCS
between the patient’s initial screening, baseline, and
final visit.

μg/dL. Their ferritin concentrations increased from
5.1 µg/L to 18.76 µg/L, visit 1 to visit 4, respectively
(p = 0.001). All patients had increased Fe status
at the completion of the study. Figure 6 shows the
changes in CCS concentrations in erythrocytes for
patients who received Fe supplementation.

A)

B)

Figure 6. CCS between visits 1 and visits 4 signiﬁcantly increase across all Fe supplemented patients (p = 0.046). (A). The image
of the Western blot for Fe supplemented patients. GAPDH was used as the control across the patients. (B). All patients’ CCS
concentrations in erythrocytes increased after undergoing Fe supplementation. Mean [SEM] CCS for visit 1 was 0.958 [0.164],
which increased to 1.247 [0.154] at visit 4.

measuring CCS concentrations in the erythrocytes
of human subjects. Further research should be
conducted to assess the reliability of the methods
used for this study.

Figure 6: CCS between visits 1 and visit 4 significantly increase across all Fe supplemented
patients (p=0.046). A) The image of the western blot for Fe supplemented patients. GAPDH
was used as the control across the patients. B) All patients’ CCS concentrations in
erythrocytes increased after undergoing Fe supplementation. Mean [SEM] CCS for visit 1
was 0.958 [0.164] which increased to 1.247 [0.154] at visit 4.

The patient with Cu deficiency that we provided
with high doses of Cu gluconate supplementation,
8 mg/day for 8 weeks, had a normalized serum Cu
status (> 70 mg/dL) at the conclusion of the study.
For this patient, 8 mg/day was a sufficient amount
of Cu supplementation to replete her Cu status by
measurement of her serum Cu. The CCS values for
this patient did not appear to change from visit 1 to
visit 4. It was surprising to only find one patient with
Cu deficiency since our lab previously saw much
higher incidence of Cu deficiency in the bariatric
surgery population (Gletsu-Miller et al., 2012).
Different geographical locations or a difference
in diet may be reasons why we are seeing less
incidence of Cu deficiency. Since Cu is affected by
inflammation, high BMI in some of the patients may
also be a factor that is affecting Cu status (Danzeisen
et al., 2007). We suspect that dietary Cu is also
associated with Cu status, but since we found only
one patient with Cu deficiency, this remains to be
determined. There is no evidence to suggest that
blood loss through menstruation has an effect on Cu
status. More patients with Cu deficiency would be
needed to determine whether this supplementation
treatment is sufficient to replete Cu status in patients
who are Cu-deficient, and to evaluate whether
erythrocyte CCS responds to changes in Cu status
following high-dose Cu supplementation.

In the other intervention, we had five patients who
were enrolled to receive Fe supplementation. As we had
expected, all the patients had a normalized Fe status
at the conclusion of the study. A previous study in our
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Figure 6: CCS between visits 1 and visit 4 significantly increase across all Fe supplemen
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independent of the level of obesity, meaning patients
who consumed less dietary Fe were more likely to be
deficient (Mischler et al., 2015). Blood losses through
menstruation or gastrointestinal problems are other
areas that may affect Fe status in patients. The Fe
supplement successfully normalized deficient patients.

There was a consistent increase in CCS from visit
1 to visit 4 in patients who were supplemented with
Fe. Previous studies have shown that Cu status is
low when Fe is high in animal models that consume
high dietary Fe, and this study saw a similar trend
in terms of erythrocyte CCS indicator of Cu status
(Gulec & Collins, 2014; Jung-Heun Ha et al., 2016).
After receiving high doses of supplementary Fe for
8 weeks, patients had a significant increase in CCS.
This implies that there is an interaction between Fe
and CCS. Because no correlation was found between
CCS and serum Cu, we cannot determine if a change in
Cu status in these patients is a potential reason for the
change in CCS.
The present study is limited by its low statistical power,
having only one patient supplemented with Cu and five
patients supplemented with Fe. However, as the study
is ongoing, the sample size will continue to increase.
The study also only recruited females and all of the
study subjects were Caucasian, so the study may not
be generalizable to men or other races. In addition, we
do not know what the serum Cu concentrations are for
those enrolled in the Fe supplementation study. We did
not record where patients were in their menstrual cycle
at the time blood draws were taken. This would have an
effect on Fe status, but there is no evidence to suggest
that the menstrual cycle affects Cu status. We are
actively working to obtain those values to explore how

serum Cu may have changed compared to erythrocyte
CCS in reaction to high doses of Fe supplementation.
While this study did not find a significant association
between CCS in erythrocytes and serum Cu in human
subjects, we did find a significant increase in CCS from
visit 1 to visit 4 in patients who received high doses of
Fe supplementation. We were also able to replete the Cu
status of the Cu-deficient patient who took high doses
of Cu supplementation, though the patient’s erythrocyte
CCS concentrations were unchanged. We will continue
to screen for patients who have Cu or Fe deficiency and
treat them with high doses or oral supplementation.
We will also continue to explore associations between
CCS in erythrocytes and serum Cu in patients who
have undergone bariatric surgery. Future studies should
explore dietary records collected and how that relates to
Cu status. Because obesity is an inflammatory disease,
future studies should investigate whether BMI and
body weight of patients affects Cu status, since serum
Cu is elevated during inflammation (Danzeisen et al.,
2007). Future studies should also explore how age of
patients may affect Cu status.
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